Research and Markets: Electronic Medical Implants.DUBLIN, Ireland -- Cardiovascular Devices for Cardiac Rhythm Management Cardiac rhythm management is a field of treatment in cardiology. The purpose is managing cardiac rhythm disorders. Usually it involves artificial pacemakers and/or implantable cardioverter-defibrillator therapy as well as antiarrhythmia drugs. , Such as Pacemakers, Implantable Cardiac Defibrillators, and Cardiac Resynchronisation Therapy (CRT (1) (C RunTime) See runtime library. (2) (Cathode Ray Tube) A vacuum tube used as a display screen in a computer monitor or TV. The viewing end of the tube is coated with phosphors, which emit light when struck by electrons. ), Are Currently Market Leaders with 80% Market Share Research and Markets (http://www.researchandmarkets.com) has announced the addition of Electronic Medical Implants to their offering. The pacemaker was the first electronic medical implant (EMI (ElectroMagnetic Interference) An electrical disturbance in a system due to natural phenomena, low-frequency waves from electromechanical devices or high-frequency waves (RFI) from chips and other electronic devices. Allowable limits are governed by the FCC. ) to be developed in the 1950's, and since then the industry has expanded to include a wide array of devices, such as vagus nerve vagus nerve n. Either of the tenth pair cranial nerves that originate from the medulla oblongata and supply multiple vital organs, including the lungs, heart, and gastrointestinal viscera. stimulators and ventricular assist devices, that address numerous indications, including epilepsy and heart failure. Additionally, innovators are bringing to market novel technologies, such as fully-implantable replacement hearts and prosthetic pros·thet·ic adj. 1. Serving as or relating to a prosthesis. 2. Of or relating to prosthetics. prosthetic serving as a substitute; pertaining to prostheses or to prosthetics. retinal implants to cure blindness from macular degeneration. Cardiovascular devices for cardiac rhythm management, such as pacemakers, implantable cardiac defibrillators, and cardiac resynchronisation therapy (CRT), are leading the market currently, with 80% market share. Medtronic will maintain the segment leader with approximately 50% share due to extensive product offerings, such as implantable drug infusion pumps, Activa neurostimulation therapy for Parkinson's disease, and CRTs, and its established worldwide EMI presence. For more information visit http://www.researchandmarkets.com/reports/c4244 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion